A crossover, open, prospective, randomized study of fixed-dose combination of carteolol/latanoprost (LCFC) and timolol/latanoprost (LTFC) in patients with primary open-angle glaucoma and ocular hypertension
Latest Information Update: 07 Sep 2021
At a glance
- Drugs Carteolol/latanoprost (Primary) ; Latanoprost/timolol (Primary)
- Indications Ocular hypertension; Open-angle glaucoma
- Focus Adverse reactions; Therapeutic Use
- 07 Sep 2021 New trial record
- 01 Sep 2021 Results published in the Japanese Journal of Ophthalmology